Andrew Kurtz, Ph.D., Program Director, Small Business Innovation Research Development Center, NCI
Andrew Kurtz, Ph.D., Program Director, Small Business Innovation Research Development Center, NCI
Dr. Kurtz has been a Program Director in the Small Business Innovation Research Development Center at the National Cancer Institute. His management portfolio includes projects focused on early-stage cancer drug development, including small molecules, biologics, and novel multifunctional therapeutics based on nanotechnology. Previously, Dr. Kurtz was an AAAS Science and Technology Policy Fellow at the NIH, during which time he served on the management team of The Cancer Genome Atlas Pilot Project. Dr. Kurtz received a PhD in Biochemistry & Molecular Biology from The University of Texas Medical Branch at Galveston.
Beth Seidenberg, M.D., Partner, Kleiner Perkins Caufield & Byers
Beth Seidenberg, M.D., Partner, Kleiner Perkins Caufield & Byers
Dr. Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and was the founding CEO of two: Arresto (sold to Gilead in 2011), focused on antibody therapeutics for cancer and fibrosis; 3-V Biosciences, focused on therapeutics for infectious diseases; Auxogyn, focused on device and diagnostics for in-vitro fertilization; Epizyme, focused on therapeutics based on epigenetic targets; and iPierian, focused on drug discovery for neurodegenerative disorders using induced pluripotent stem cells (iPS). Beth serves on the board of directors of 3-V Biosciences, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO. Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth is the chairman and founder of NVCA-MedIC coalition, which focuses on FDA reform, and she is an advocate for fast and safe access to innovative products. She also serves on the foundation board at the Gladstone Institute and the Stanford Coulter Foundation oversight committee. Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
Corey Goodman, Ph.D., Managing Partner & Co-founder, venBio LLC
Corey Goodman, Ph.D., Managing Partner & Co-founder, venBio LLC
Dr. Goodman is a renowned scientist, entrepreneur, educator, CEO, and corporate executive. He was formerly President of Pfizer's Biotherapeutics and Bioinnovation Center, and a member of Pfizer's Executive Leadership Team. Dr. Goodman was a co-founder of Exelixis, Renovis, Second Genome, and Ossianix, and CEO of Renovis until its acquisition by Evotec. He is a former professor at Stanford University and UC Berkeley, co-founder of Berkeley's Wills Neuroscience Institute, an Investigator with the Howard Hughes Medical Institute, and currently an Adjunct Professor at UC San Francisco. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award from the National Science Board, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Trinity College Dublin Dawson Prize in Genetics. He is on the Board of the California Council on Science and Technology, the Pacific Institute, and former chair of the National Academy of Sciences' Board on Life Sciences. He is an advisor to several university innovation centers and disease foundations. He is Chair of the Board of several companies, including Oligasis, Ossianix, and Second Genome, and a member of the Board of several others, including NeuroTherapeutics and Mirna. Dr. Goodman is located in venBio's San Francisco office.
Diego Miralles, M.D., Head, Janssen Research & Development and Janssen Healthcare Innovation
Diego Miralles, M.D., Head, Janssen Research & Development and Janssen Healthcare Innovation
Dr. Diego Miralles is the management sponsor of Janssen Labs as part of his role as site head of the Janssen West Coast Research Center, part of Janssen Research & Development LLC. He oversees the business and operational management of Janssen Labs including the initial concept development, site construction, business model architecting, and company selection criteria. Miralles is also Head of Janssen Healthcare Innovation (JHI), a newly created team within Janssen R&D. JHI is actively testing and launching more than a dozen new business models. The team is focused on enhancing the value of our existing pharmaceutical business by identifying and integrating emerging technologies and novel partnerships in the following areas – clinical trials, adherence and genomics. The team is also identifying business opportunities in newly created markets such as innovative financing of healthcare, optimizing healthcare delivery and health maintenance. Miralles currently serves as an adjunct full professor in the Pharmacology department at the University of California, San Diego and is on the Board of Rady Children’s Hospital. His background includes over 13 years in the healthcare industry and 12 years in the hospital and academic worlds. Prior to heading the West Coast Research Center he was involved in the development of several drugs that made it to the market, including FTC, T-20, Prezista, Intellence and Edurant. He has extensive experience in clinical research, mostly in the HIV/AIDS space, including work on antiviral drug development at Belgium’s Tibotec BVBA, Trimeris, Inc, and Triangle Pharmaceuticals. Miralles was previously on the faculty at Duke University, Durham, NC, where he had a clinical HIV practice after serving as attending in charge at The AIDS Clinical Trial Unit, Beth Israel Medical Center, NY. He completed his fellowship in Infectious Diseases at Cornell University-New York Hospital after a residency in Internal Medicine at the Mayo Clinic in Rochester, MN. He graduated from the University Of Buenos Aires School Of Medicine in 1986.
Doug Fisher, M.D., InterWest Partners
Doug Fisher, M.D., InterWest Partners
Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical, diagnostic, and medical device investments. He is a board member of Cardiac Dimensions, Gynesonics, Obalon Therapeutics, Sera Prognostics and USDS. Doug also is actively involved in InterWest's investments in Integrated Diagnostics and Invuity. Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix. Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in new disease areas for Remicade. Doug received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.
Mark Gudiksen, Ph.D., Principal, TPG Biotech
Mark Gudiksen, Ph.D., Principal, TPG Biotech
Dr. Gudiksen joined TPG Biotechnology in 2008, with a focus on both healthcare and industrial biotechnology. Prior to joining TPG Biotechnology, Dr. Gudiksen was at McKinsey & Company where he worked on a broad spectrum of strategic topics and M&A opportunities. Prior to this, Dr. Gudiksen received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. His doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal. Dr. Gudiksen currently serves on the boards of directors of Alphabet Energy, Inc., Auxogyn, Inc. and Nodality, Inc., and is a board observer at DNAnexus, Inc.
Mike Hoerres, MS, Principal, Geisinger Ventures
Mike Hoerres, MS, Principal, Geisinger Ventures
A Principal in Geisinger Ventures, Mike Hoerres is responsible for working with colleagues in Geisinger research and the Geisinger Clinic to commercialize new discoveries in the life sciences, genomics and proteomic research areas that will ultimately lead to improvements in patient care. A seasoned professional with extensive entrepreneurial and operations experience in life science and biopharmaceutical companies, Mr. Hoerres brings to the position exceptional industry and scientific knowledge. He is skilled at strategic counsel as well as the hands-on support to foster growth in new projects. Prior to joining Geisinger, Hoerres was Vice President of Business Development at Source MDx, where he shepherded the licensing of the Source MDx platform for use in the clinical trial businesses of the nation’s two largest reference laboratories. He also developed biomarker and companion diagnostic collaborative agreements, including licensing rights to companion diagnostics and stand-alone diagnostics, based on collaborative research plans. Prior to that, he served as Clinical Market Development Manager at Affymetrix and Director of Business Development at Incyte Genomics. Hoerres holds a BS in biochemistry of University of Wisconsin – Milwaukee and a MS in molecular immunology from San Diego State University.
Myla Lai-Goldman, M.D., Managing Partner Personalized Science, LLC
Myla Lai-Goldman, M.D., Managing Partner Personalized Science, LLC
In 2009, Dr. Lai-Goldman founded and became the managing partner of Personalized Science, LLC, a consulting company whose mission is to assist its customers achieve successful adoption of innovative diagnostics with actionable results for patient’s unmet medical needs. In 2011, Dr Lai-Goldman founded and became CEO of GeneCentric Diagnostics, Inc., focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions. Additionally, Dr. Lai-Goldman became a Venture Partner with Hatteras Venture Partners, Inc, a venture capital firmed based in Research Triangle Park, NC. Until her retirement on December 31, 2008, Myla P. Lai-Goldman, M.D. was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), From 1998 until April 2008, Dr. Lai-Goldman also served as Chief Scientific Officer of the company. Dr. Lai-Goldman joined the Company in 1990. Dr. Lai-Goldman earned an MD from the College of Physicians and Surgeons at Columbia University in New York. She is board-certified in anatomic and clinical pathology.
Risa Stack, Ph.D., General Manager, GE’s Emerging Health Innovations
Risa Stack, Ph.D., General Manager, GE’s Emerging Health Innovations
Dr. Risa Stack is a partner at Kleiner Perkins Caufield & Byers. Since joining the firm in 2003, she has worked to build and support KPCB’s personalized medicine portfolio. Risa has been the founding CEO and a board member of several personalized medicine companies, including CardioDx and Nodality. Risa is a board observer at Tethys, Veracyte and Xdx. In addition to her work directly with portfolio companies, Risa is involved in developing public policy in molecular diagnostics and personalized medicine. Risa is also involved in the development of therapeutics companies, including Corthera and Trius. She was most recently a board member of Corthera (sold to Novartis in 2009), and she is a board observer at Epizyme and Pacific Biosciences. Risa has 15 years of experience investing in personalized medicine, therapeutics and platform technologies. Her investment career spans from incubations to public companies. Most recently, she has focused on starting companies, often taking operational roles. Before joining KPCB, Risa was a principal at J.P. Morgan Partners in the life science practice for six years. While at J.P. Morgan Partners, she sponsored a series of investments including Acurian, Connetics (acquired by Steifel Laboratories), Diatide (acquired by Berlex), Ilex Oncology (acquired by Genzyme), Illumina, and Triangle Pharmaceuticals (acquired by Gilead). Risa was also involved in JP Morgan Partners’ international investing efforts, which included European life sciences companies and managing a portfolio of Israeli early stage life sciences and IT companies. Before joining the venture capital industry, Risa worked as a derivative specialist on the Chicago Board of Trade, where she traded futures and options on government securities.Risa received her B.S. degree in genetics and development with distinction from the University of Illinois and her Ph.D. in immunology from the University of Chicago. She was also a member of the second class of Kauffman Fellows. Risa also serves as a member of the advisory board of the National Summit on Personalized Healthcare and GE’s Healthymagination effort. In 2004, Risa was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times.
Stacy Feld, Partner, Physic Ventures
Stacy Feld, Partner, Physic Ventures
Stacy Feld, J.D., is a Partner at Physic Ventures. Stacy focuses on personalized health solutions to improve and transform care for the health consumer. Specifically, Stacy is interested in life science opportunities offering more precise prevention, diagnosis, and treatment of chronic disease. She is on the board of T2 Biosystems and an observer on the boards of On-Q-ity and Own.
Steve Eichenlaub, Managing Director, Platform Technologies, Cleantech, and Health Sector, Intel Capital
Steve Eichenlaub, Managing Director, Platform Technologies, Cleantech, and Health Sector, Intel Capital
Steve has been with Intel and Intel Capital since 1998. He is a member of investment committees for Platform Technologies, Cleantech, and Healthcare investments. Steve leads a worldwide team of investment managers driving equity and technology licensing with companies at all stages of growth, to accelerate the frontiers of technology related to Intel’s long-term strategic interests while driving positive financial return. Prior to Intel, Steve worked at Adobe Systems and Mentor Graphics, and at start-ups Silicon Compiler Systems and GammaMetrics, across a variety of roles spanning venture investing, M&A, business development, strategic and product marketing, sales, and investor relations. He holds a BS in Electrical and Nuclear Engineering from UC Berkeley, and an MBA from Harvard Business School.
Ted Apple, Ph.D., Partner, Kilpatrick Townsend
Ted Apple, Ph.D., Partner, Kilpatrick Townsend
Dr. Apple is a partner at the law firm of Kilpatrick Townsend & Stockton LLP. His practice is focused on patent acquisition and counseling in the biotechnology and pharmaceutical industries. In addition to patent prosecution in the U.S. and abroad for clients such as Fluidigm, Complete Genomics, Codexis, and Threshold Pharmaceuticals, Ted’s practice includes validity and noninfringement analyses, portfolio review in connection with venture capital financing, and representation of clients in contested proceedings before the USPTO. Ted has experience in a number of technical and legal areas, including molecular biology, biologics, diagnostics, genetics, immunology, microfluidics, and pharmaceutical re-purposing strategies. Ted received his Ph.D. at U.C. Berkeley and, prior to practicing law, was a post-doctoral fellow at Genentech, Inc.
Warren H. Hogarth, Partner, Sequoia Capital
Warren H. Hogarth, Partner, Sequoia Capital
Warren H. Hogarth focuses on bioinformatics, SAAS and energy companies. He is a Director of Silicon Valley Biosystems and FutureAdvisor and a Board Observer of AssureRx, C12 Energy and SunRun. Prior to joining Sequoia Capital in 2008, Warren completed his Ph.D. in Chemical Engineering from the University of Queensland in Australia, during which time he was a Fulbright Scholar at Princeton University and a Guest Scientist at the Fraunhofer Institute in Germany. In addition to his Ph.D., Warren has an M.B.A. from Harvard Business School and a B.E. and B.Comm. from the University of Queensland.
